AVTX
INSIDER SELLAvalo Therapeutics, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeAvalo reported Q2 2026 results with positive Phase 2 LOTUS data for abdakibart in hidradenitis suppurativa, securing runway into 2029 with $472.2M cash and planning Phase 3 initiation in H1 2027. However, the company missed EPS consensus by $0.25 ($0.83 actual vs. $0.58 estimate), a 43% miss, driven by higher R&D and G&A expenses than implied by consensus.
Red flags
- •EPS miss of $0.25 per share (43% below consensus estimate)
- •Net loss of $36.4M in Q2 2026 with elevated operating expenses ($23.4M R&D + $8.1M G&A)
- •Phase 3 initiation dependent on first half 2027 execution; no guarantee of regulatory approval pathway clarity
Insider Activity
| Name | Title | Type | Shares | Price | Value | Filed | Src |
|---|---|---|---|---|---|---|---|
| Sullivan Christopher Ryan | Chief Financial Officer | SELL | 31K | $20.05 | $0.62M | 2026-08-18 | ↗ |
| Sullivan Christopher Ryan | Chief Financial Officer | SELL | 38K | $19.85 | $0.75M | 2026-08-17 | ↗ |
| Sullivan Christopher Ryan | Chief Financial Officer | SELL | 4K | $19.94 | $0.07M | 2026-08-17 | ↗ |
| Doyle Mittie | Chief Medical Officer | SELL | 1K | $20.00 | $0.02M | 2026-08-17 | ↗ |
| Riley Jennifer | Chief Strategy Officer | SELL | 3K | $19.59 | $0.05M | 2026-08-11 | ↗ |
| Doyle Mittie | Chief Medical Officer | SELL | 679 | $20.00 | $0.01M | 2026-08-10 | ↗ |
| Doyle Mittie | Chief Medical Officer | SELL | 1K | $20.00 | $0.02M | 2026-07-27 | ↗ |
| Doyle Mittie | Chief Medical Officer | SELL | 5K | $20.00 | $0.09M | 2026-06-30 | ↗ |
Fund 13D/13G Filings (2)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
Tracked Funds Holding (1)
| Fund | Manager | Shares Held | Position Value |
|---|---|---|---|
| Point72 | Steve Cohen | 2.4M | $44M |
Quarter-end 13F positions for the tracked funds holding this stock.